AstraZeneca drug succeeds in trial for swallowing disorder
AstraZeneca drug succeeds in trial for swallowing disorder Proactive uses images sourced from Shutterstock AstraZeneca PLC (LSE:AZN, NASDAQ:AZN)…
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
AstraZeneca AZN announced that it is discontinuing a phase III study called eVOLVE-Lung02, evaluating its experimental bispecific antibody, volrustomig,…
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda
AstraZeneca has ended a Phase III trial of its bispecific volrustomig pitted against MSD’s blockbuster Keytruda (pembrolizumab) in…
AstraZeneca: Zoladex to stay free for cancer, endometriosis patients
A lifesaving drug will remain accessible to patients struggling with cancer and endometriosis. AstraZeneca announced that Zoladex, a…
United Kingdom Researchers Integrate C2N’s PrecivityAD2® Blood Test Into the Alzheimer’s Disease Diagnostic Care Pathway
ST. LOUIS, July 29, 2026–(BUSINESS WIRE)–Researchers in the United Kingdom are using the PrecivityAD2® blood test from C2N…
AstraZeneca’s £19bn blow as Wainua heart drug fails key late-stage trial
AstraZeneca’s £19bn blow as Wainua heart drug fails key late-stage trial Proactive uses images sourced from Shutterstock AstraZeneca…
AstraZeneca’s £19bn blow as Wainua heart drug fails key late-stage trial
AstraZeneca’s £19bn blow as Wainua heart drug fails key late-stage trial Proactive uses images sourced from Shutterstock AstraZeneca…
GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer
GSK plc GSK has announced positive interim data from a mid-stage study evaluating its oncology drug, Jemperli (dostarlimab), in…
AstraZeneca Gets a Rare Clinical Black Eye
AstraZeneca Gets a Rare Clinical Black Eye – Moby THE GIST Our analysts just identified a stock with…
AstraZeneca Shares Slide After Heart Drug Trial Misses Primary Endpoint
MT Newswires -Shutterstock AstraZeneca’s (AZN.L, AZN.ST) shares fell sharply on Thursday morning after the British drugmaker disclosed that…
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 1, 2026 /PRNewswire/ — Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter, HKEX code: 02256.HK) today announced…
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA),…